---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016890"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:54:04.791130+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics Q2 net loss widens to $28.1M; cash runway into 2025; expands 4D-310 trial to females

## Summary
- Net loss of $28.1M in Q2 2022 vs $7.6M in Q2 2021; revenue fell to $0.2M from $14.6M.
- Cash and equivalents of $261.6M as of June 30, 2022, expected to fund operations into first half 2025.
- R&D expenses rose to $20.4M from $15.2M; G&A to $8.2M from $7.0M.
- 4D-310 Phase 1/2 expanded to include female Fabry patients; new steroid-sparing immunosuppression cohort added; data update expected 1H 2023.
- Five clinical-stage candidates on track for multiple clinical data updates in 2023.

## SEC filing metadata
- accession: 0000950170-22-016890
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017022016890/0000950170-22-016890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017022016890/fdmt-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016890
- JSON: https://secwatch.observer/filing/0000950170-22-016890.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016890.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.